Fig. 1: Differential expression of SUV39H1 and distribution of H3K9me3 in MLL-r AML LSCs in comparison with normal counterparts.

a Expression levels of SUV39H1 in our in-house collected samples: bone marrow (BM) CD34⁺ cells from donors and AML patients. Data are presented as means ± s.e.m., *P < 0.05, Student’s t test. b, c Expression levels of Suv39h1 in leukemic stem cell-enriched groups (defined as c-Kit⁺ in b, and as L-GMP, IL-7R^–Lin^–Sca-1^–c-Kit⁺CD34⁺CD16/32⁺ in c) isolated from two MLL-r AML mouse models compared with the expression in normal murine HSPCs. MA9, MLL-AF9; MN3, MLL-NRIP3 (see Materials and Methods). Data are presented as means ± s.e.m., n = 3, *P < 0.05, **P < 0.01, Student’s t test. d Heat maps showing ChIP-seq signal of H3K9me3 at TSSs ± 2 kb regions for all genes in c-Kit⁺ cells isolated from WT or MLL-r leukemic mice. e Box plots showing changes in ChIP-seq signals of H3K9me3 at TSSs ± 2 kb regions of genome in c-Kit⁺ cells isolated from WT or MLL-r leukemic mice. ***P < 0.001, Wilcoxon test.